Subscribe To

Price Alert Latest News Economic Calendar News

HZNP / Horizon Therapeutics Public Limited Company (HZNP) CEO Tim Walbert on Q2 2022 Results - Earnings Call Transcript

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP ) Q2 2022 Results Earnings Conference Call August 3, 2022 8:00 AM ET Company Participants Tina Ventura - Senior Vice President, Chief Investor Relations Officer Tim Walbert - Chairman, President and Chief Executive Officer Elizabeth Thompson - Executive Vice President, Research & Development Aaron Cox - Executive Vice President and Chief Financial Officer Andy Pasternak - Executive Vice President, Chief Strategy Officer Conference Call Participants Chris Schott - J.P. Morgan Ken Cacciatore - Cowen and Company, LLC David Amsellem - Piper Sandler Annabel Samimy - Stifel, Nicolaus & Company, Inc. Michael Ulz - Morgan Stanley Robert Palermo - Goldman Sachs Jason Gerberry - Bank of America Amy Li - Jefferies LLC Derek Archila - Wells Fargo Securities Gary Nachman - BMO Capital Markets Corp. Operator Good morning and thank you for standing by. Read More

Demo Live Account See Partner Details

Content Topics

Horizon

Therapeutics

Public

Limited

Company

HZNP

Walbert

hznp

Results

Earnings

Transcript

Stock

Posted: Aug 3 2022, 10:43

Author Name: Seeking Alpha

HZNP News

By Zacks Investment Research
August 28, 2023

Horizon (HZNP) Up as FTC Pauses Acquisition by Amgen Lawsuit

The Federal Trade Commission suspends its ongoing lawsuit to block Horizon's (HZNP) acquisition by Amgen until Sep 18, 2023. The company's stock rises

By Investopedia
August 28, 2023

Horizon Therapeutics Shares Surge As FTC Postpones Challenge to Merger

Horizon Therapeutics (HZNP) shares jumped more than 5.5% in early trading Monday after the FTC said it would suspend its challenge to Amgen's (AMGN) a

By Zacks Investment Research
August 9, 2023

Horizon (HZNP) Q2 Earnings Top, Krystexxa & Uplizna Boost Sales

Horizon (HZNP) reports better-than-expected second-quarter results, beating both earnings and sales estimates, with the top-line key contributors bein

By Zacks Investment Research
August 8, 2023

Compared to Estimates, Horizon Therapeutics (HZNP) Q2 Earnings: A Look at Key Metrics

The headline numbers for Horizon Therapeutics (HZNP) give insight into how the company performed in the quarter ended June 2023, but it may be worthwh

By Zacks Investment Research
August 8, 2023

Horizon Therapeutics (HZNP) Surpasses Q2 Earnings and Revenue Estimates

Horizon Therapeutics (HZNP) came out with quarterly earnings of $1.20 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compare

By Zacks Investment Research
July 24, 2023

Horizon's (HZNP) Daxdilimab Fails to Meet Goal in Lupus Study

Horizon (HZNP) fails to meet the primary endpoint in the mid-stage study of evaluating daxdilimab in the treatment of systemic lupus erythematosus.

By Zacks Investment Research
June 2, 2023

Why Is Horizon Therapeutics (HZNP) Down 9% Since Last Earnings Report?

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock?

By Seeking Alpha
May 29, 2023

Amgen: Appeal Becomes Visible Despite Uncertainty On The 'Horizon'

Amgen's stock has seen a further pullback since it announced an acquisition of Horizon Therapeutics in December. Shares are down by nearly a quarter a

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.